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Abstract
Background: Alpha-1-antitrypsin deficiency (AATD) is a rare inherited condition caused by mutations of the SERPINA1
gene that is associated with the development of a COPD like lung disease. The comorbidities in patients with AATD-
related lung diseases are not well defined. The aim of this study was to analyze the clinical phenotype of AATD
patients within the German COPD cohort study COSYCONET (“COPD and SYstemic consequences-COmorbidities
NETwork”) cohort focusing on the distribution of comorbidities.
Method and results: The data from 2645 COSYCONET patients, including 139 AATD patients (110 with and 29 without
augmentation therapy), were analyzed by descriptive statistics and regression analyses. We found significantly lower
prevalence of cardiovascular comorbidities in AATD patients as compared to non-AATD COPD patients. After correction
for age, pack years, body mass index, and sex, the differences were still significant for coronary artery disease (p = 0.002)
and the prevalence of peripheral artery disease as determined by an ankle-brachial-index <= 0.9 (p = 0.035). Also the
distribution of other comorbidities such as bronchiectasis differed between AATD and non-deficient COPD.
Conclusion: AATD is associated with a lower prevalence of cardiovascular disease, the underlying mechanisms need
further investigation.
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Background
Alpha-1-antitrypsin deficiency (AATD) is a rare inher-
ited condition caused by mutations of the SERPINA1
gene and is a genetic risk factor for liver and lung dis-
ease [1, 2]. AATD is a model disease to explain the
pathogenesis of chronic obstructive pulmonary disease
(COPD) based on a dysbalance of proteases and antipro-
teases. COPD is a heterogeneous disorder with several
phenotypes [3]. Comorbidities often complicate the clin-
ical presentation of patients with COPD and comprise
cardiovascular and cerebrovascular diseases, osteopor-
osis, depression, lung cancer, and diabetes [4]. Reduction
in lung function is an independent risk factor for the
presence of cardiovascular diseases [5] and the presence
of cardiac disease impacts on the natural history of
COPD and vice versa [6].
Only a few studies have investigated the comorbidity
profile of AATD patients and found increased risk for aor-
tic stiffness and musculoskeletal changes as compared to
smokers without COPD [7] as well as a higher prevalence
of bronchiectasis as compared to historical data [8]. Some
studies reported that AATD patients without COPD have
a lower risk for developing cardiovascular diseases as
compared to PiMM individuals [9, 10], however this issue
remains controversial [11, 12].
The aim of the present study was to analyze the clinical
phenotype of AATD patients within the German COPD
cohort “COPD and Systemic Consequences-Comorbidities
Network” (COSYCONET). For this purpose, we identified
AATD patients in the study cohort and analyzed their basic
anthropometric data, pulmonary function parameters, and
the presence of comorbidities with a focus on cardiovascu-
lar diseases.
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Methods
Patient description
We used the baseline dataset of the COSYCONET cohort
study (visit 1), which is a prospective, multicentre, observa-
tional study. In total, 2741 patients were recruited from
September 2010 to December 2013 in 31 study centers
throughout Germany. Patients were eligible if they were
≥40 years of age and had a diagnosis of COPD or symp-
toms of chronic bronchitis. Exclusion criteria were previous
lung transplantation, lung volume reduction surgery and
lung malignancies, and the presence of moderate or severe
exacerbation within the last 4 weeks. Further details of the
study have been reported elsewhere [13].
Patients were classified for COPD severity based on
two different methods, GOLD criteria using the 2009
spirometric classification I-IV and the 2011 classification
A-D based on the CAT score and spirometry (www.gold-
copd.com). For the spirometric classification (GOLD
2009), patients showing a ratio of FEV1/FVC < 70% were
allocated according their FEV1%pred and patients having
a ratio of FEV1/FVC > 70% were classified as “at risk”
for COPD or GOLD stage 0 [14] if they: (i) had a
doctor’s diagnosis of chronic bronchitis, (ii) reported a
severity of cough ≥3 points on the respective COPD
Assessment Test (CAT) items and/or (iii) reported a
severity of phlegm ≥3 points on the respective CAT
item. The current analyses included all patients with
GOLD stages 0-IV. Patients with missing severity stage
(n = 19) and unclassified patients according to GOLD
and the above definition (n = 77) were excluded from
the analysis resulting in a sample of n = 2645 patients.
Ethics, consent and permissions
The COSYCONET study was approved by the Ethics
Committees of the local study centers. All cohort partic-
ipants gave their written informed consent.
Definition of alpha-1-antitrypsin deficiency (AATD)
The dataset of visit 1 comprised self-reported informa-
tion on AATD, medication, and laboratory measurement
of the serum AAT concentration. Genotyping data for
the SERPINA1 gene were not available for most of the
patients. Patients with known AATD were asked to spe-
cify this condition and the underlying genotype. Patients
were assigned to two major groups: 1) COPD patients
without AATD (“COPD”): Patients with no historical in-
formation of AATD, no augmentation therapy and nor-
mal AAT serum level. Patients with known heterozygous
PiMZ status were classified as “COPD without AATD”.
2) Patients with (severe) AATD (“AATD”): Patients with
known homozygous PiZZ or other homozygous deficiency
mutations, patients with augmentation therapy. For miss-
ing genotypes, the medication and AAT serum concentra-
tion were evaluated: Subjects with AAT augmentation
therapy with an AAT serum concentration value <50 mg/
dl were classified as “COPD with AATD”. Based on the
presence of augmentation therapy, the “AATD” group was
subdivided into AATD with augmentation therapy
(“AATD + T”) and without (“AATD-T”). Medication lists
were screened for all patients and presence of augmenta-
tion therapy led to the classification as AATD patient.
Measurements
Clinical history including information on smoking habits
and comorbidities was accessed during visit 1. A 6-min
walk test (6MWT) was performed according to the 2002
ATS guidelines [15]. The BODE index was computed
using the algorithm developed by Celli and colleagues
[16]. For the time-up-and-go-test, the duration of the
procedure (stand up from the sitting position, walk of
3 m distance and back and sit down again) was mea-
sured [17]. Pulmonary function testing by spirometry
and body plethysmography was performed according to
the ATS/ERS guidelines [18] and reference equations
were used as described by the Global Lung Function Ini-
tiative (GLI) [19]. The diffusing capacity for carbon
monoxide (TLCO) was determined by the single-breath
technique following the ERS/ATS guidelines [20]. The
ankle-brachial Index, ABI) was measures as described [21]
and an ABI of <0.9 was considered abnormal according to
the American College of Cardiology Foundation/American
Heart Association Task Force Practice Guidelines [22].
Within COSYCONET, patients were asked to make their
CT scans available for analysis. These were visually assessed
for emphysema and airway changes by a senior radiologist
with more than 15 years of experience in chest imaging and
COPD. In a lobe-based approach, emphysema was rated
semi-quantitatively on a five-point scale for each lobe as
follows: <5%, 5–25%, 26–50%, 51–75%, >75%. The emphy-
sema was classified as being centrilobular, including coales-
cent centrilobular emphysema or panlobular, including
advanced destructive emphysema [23]. Large airways were
assessed for the presence of bronchiectasis and wall thick-
ening, small airways for centrilobular nodules and mosaic
attenuation pattern. Finally, a decision was made whether
the predominant component of the disease was emphy-
sema or abnormalities of the airways.
Statistical analysis
The statistical analysis was performed using SAS software
version 9.3 (SAS Institute Inc., Cary, NC, USA). P-values
≤0.05 were considered statistically significant. For quanti-
tative variables, results are shown as lsmean, difference
between lsmeans with CI 95% and p-values from GLM (if
not stated otherwise). The General Linear Models (GLM)
procedure is a method of linear regression that uses the
method of least squares and is more robust for variables
that do not show a normal distribution. Least squares
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means (lsmean) refers to as marginal means (or some-
times EMM - estimated marginal means). In an analysis of
covariance model, they are equivalent to the group means
after having controlled for a covariate. Categorical vari-
ables are reported as absolute and relative (%) frequencies
and chi-square tests were performed to compare groups.
Results are visualized using (grouped) bar charts, histo-
grams or forest plots.
In order to adjust the comparisons for potential con-
founders, multivariate regression analyses and subgroup
analyses were conducted. Comorbidities were compared
using logistic regression models adjusted for sex, age
groups, pack years, FEV1% pred (GLI), BMI and hyperten-
sion (yes/no). Sensitivity analyses omitting hypertension as
influencing factor were performed. A Forest plot was used
to visualize the adjusted odds ratios (ORs) of selected
comorbidities with corresponding 95%-confidence intervals.
Differences regarding laboratory parameters were analyzed
with linear regression adjusted for sex, age groups, pack
years, FEV1% predicted and BMI.
An overall sensitivity analysis was applied in a selected
dataset matching 3 non-AATD patients to each AATD
patient. Matching criteria were sex, age (± 5 years) and
pack years (± 10 years). For all AATD patients but one,
3 controls could be found. Comparisons in this dataset
were performed in line with the analysis strategy out-
lined above.
Results
Patient characteristics
A total of 139 patients with AATD were identified (5.2%
of total cohort). Of these, 110 patients (79.1%) received
AAT augmentation therapy, whereas 29 patients (20.9%)
reported no augmentation therapy or information on
this therapy was missing. The AATD group comprised
106 Pi ZZ patients (78.5%), 2 with PiSZ genotype, 20
with unknown genotype but augmentation therapy and
11 patients with unknown genotype and no or unknown
augmentation treatment. These 11 patients were classi-
fied as AATD patients because of the low serum levels
of AAT (< 50 mg/dl). The group of COPD subjects with-
out AATD included 8 patients with self-reported AATD
of genotype Pi MZ, 16 patients with self-reported AATD
of unknown genotype but normal AAT serum level and
no replacement treatment, and 2482 patients without
AATD according to self-report and medication.
The characteristics of the individuals with AATD with
(“AATD + T”) or without augmentation therapy (“AATD-T”)
and individuals with COPD only (“COPD”) are shown in
Table 1. As expected, there were significant differences be-
tween COPD and AATD patients. AATD patients were youn-
ger, had a lower BMI, and had smoked considerably less.
AATD-T as compared to AAT + T patients were younger,
showed less severe lung disease and better performance in the
6-MWT.
We next focused on the lung disease phenotype (Table 2).
As compared to non-deficient COPD, AATD + T patients
showed more severe airflow limitation as indicated by sig-
nificantly lower FEV1%pred, lower FEV1/FVC and in-
creased effective specific airway resistance sRaweff %pred.
In contrast, AATD-T individuals had less airflow limitation
as compared to the COPD or AATD + T groups. Some
patients provided CT scans obtained for the clinical pur-
poses up to 4 years prior to inclusion into our study. In
total, 356 CT scans from 2506 COPD patients (14.2%) and
23 CT scans from 139 AATD patients (16.5%) were avail-
able, which did not allow to perform AATD patients group-
ing according to augmentation therapy. Hence, AATD
patients showed more emphysema, with 16% having an in-
volvement of more than 75% of lung as compared to only
3% within COPD group (Additional file 1: Table S1). At the
same time, wall thickening of the airways was less fre-
quently observed in the AATD group, while bronchiectasis
was more frequent as compared to the COPD group.
Next we performed a multivariate regression analysis
with TLCO %pred as dependent variable, which is related
to emphysema and linked to other parameters that differ
between AATD and COPD groups [24]. The presence of
AATD was associated with a significant reduction of
TLCO %pred after adjustment for airway obstruction in
terms of FEV1% pred, lung hyperinflation in terms of
ITGV %pred and for COPD risk factors, such as smoking
(pack-years) and BM (Fig. 1 and Additional file 1: Table
S2). This difference is illustrated for ITGV%pred in
Additional file 1: Figure S1A, B and for BMI in Additional
file 1: Figure S1C, D. The reduction of TLCO in AATD is
greater than expected from other parameters known to be
associated with COPD and emphysema.
Sensitivity analysis in a dataset matched for age, sex
and pack years was performed. In the matched dataset,
AATD-COPD patients (n = 138) had a similar 6-min
walk distance and a comparable time-up-and-go test as
patients of the COPD group (n = 414) (6-MWT:
437 ± 111 vs. 440 ± 11 m, time-up-and-go: 6.0 vs. 6.2 s
as median time). Differences in pulmonary assessments
remained highly significant in the matched dataset. sRa-
weff showed a (nearly significant) trend towards
increased airflow resistance in the AATD-COPD pa-
tients with a median of 133%pred. as compared to
115%pred. in patients without AATD (p = 0.053).
Cardiovascular diseases are less frequent in AATD + T
patients after adjustment for potential confounders
In a first step, we analyzed lung-specific comorbid
entities, for which AATD individuals reported increased
prevalence of bronchiectasis as compared to the COPD
patients (Fig. 2).
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Next, we analyzed the distribution of extra-pulmonary
comorbidities and found significant differences between
AATD and COPD patients, with particularly lower fre-
quencies of cardiovascular and related diseases (hyperten-
sion, chronic heart failure, diabetes, cardiac infarction, and
cardiac arterial disease) in AATD (Fig. 3). These changes
were concordant for patients with and without augmenta-
tion therapy and remained significant when AATD + T
and AATD-T were combined (prevalence in COPD vs.
AATD: hypertension 57 vs. 41%, chronic heart failure 11
vs. 2%, diabetes without insulin 9 vs. 3%, cardiac infarction
9 vs. 1%, and cardiac arterial disease 3 vs. 17%). Logistic
regression models with adjustment for sex, age, pack
years, FEV1%pred, BMI and hypertension revealed signifi-
cant differences between CODP and AATD + T patients
for selected comorbidities (Fig. 4 and Additional file 1:
Table S3). The number of AATD-T patients was too low
to perform this type of analysis. These data indicate that
in AATD + T patients cardiovascular diseases were less
frequent after adjustment for potential confounders. Based
on the small number of patients without augmentation,
no conclusion can be drawn about the effect of therapy.
AATD is associated with lower triglyceride and lower
HbA1c levels
To reveal whether AATD patients have altered levels of
biochemical risk markers for cardiovascular disease in
the blood, we analyzed laboratory data (Table 3). Levels
of triglycerides were lower in the AATD + T group,
while cholesterol was higher in the AATD-T group.
HDL-cholesterol was higher in AATD patients inde-
pendent of augmentation therapy. HbA1c was lower in
Table 1 Comparison of patient characteristics of the analysis population
Total 2645 1 AATD + T (110) 2 AATD-T (29) 3 COPD (2506) Diff. between means (CI95%)
p-value
Male sex 1572 (59.4%) 67 (60.9%) 10 (34.5%) 1495 (59.7%) 1 vs. 3: 1.05 (0.71 1.56) 0.791 ~
2 vs. 3: 0.36 (0.16 0.77) < .01
Age (years) 65.00 (64.67–65.33) 59.47 (57.88–61.07) 61.28 (58.18–64.38) 65.29 (64.95–65.62) 1–2: −1.80 (−5.28–5.29) 0.310
1–3: −5.81 (−7.44–4.19) < .0001
2–3: −4.02 (−7.13–0.90) 0.012
COPD duration
(years)
7.80 (7.53–8.06) 11.24 (9.95–12.53) 9.57 (7.02–12.13) 7.63 (7.35–7.90) 1–2: 1.67 (−1.19 4.52) 0.254
1–3: 3.61 (2.29 4.92) < .0001
2–3: 1.95 (−0.63 4.51) 0.138
Weight (kg) 78.91 (78.22–79.59) 75.11 (71.75–78.47) 74.28 (67.73–80.83) 79.13 (78.43–79.83) 1–2: 0.83 (−6.53 8.19) 0.824
1–3: −4.02 (−7.46–0.59)0.022
2–3: −4.86 (−11.5 1.73) 0.149
BMI 26.97 (26.76–27.17) 24.59 (23.59–25.59) 24.76 (22.81–26.71) 27.10 (26.89–27.31) 1–2: −0.17 (−2.36 2.02) 0.881
1–3: −2.51 (−3.53–1.48) < .0001
2–3: −2.34 (−4,30–038) 0.019
Packyears 44.31 (42.91–45.72) 16.3 (9.54–23.04) 11.8 (−1.37 24.91) 45.9 (44.52–47.35) 1–2: 4.52 (−10.26 19.29) 0.549
1–3: −29.6 (−36.54–
22.75) < .0001
2–3: −34.16 (−47.38–
20.94) < .0001
SGRQ Score 43.05 (42.28–43.81) 45.86 (42.13–49.59) 34.45 (27.18–41.71) 43.02 (42.24–43.81) 1–2: 11.41 (3.25 19.58) 0.006
1–3: 2.82 (−099 6.62) 0.148
2–3: −8.59 (−15.90–1.29) 0.021
CAT 18.00 (17.72–18.28) 18.79 (17.41–20.17) 16.59 (13.92–19.25) 18.15 (17.86–18.44) 1–2: 2.20 (−0.80 5.20) 0.151
1–3: 0.63 (−0.78 2.04) 0.382
2–3: −1.57 (−4.25 1.11) 0.251
EQ5D 0.82 (0.81–0.83) 0.83 (0.79–0.87) 0.87 (0.80–0.95) 0.82 (0.81–0.82) 1–2: −0.04 (−0.13 0.04) 0.324
1–3: 0.01 (−0.03 0.06) 0.488
2–3: 0.06 (−0.02 0.13) 0.142
6-min-walk
distance (m)
419.29 (415.10–423.48) 421.86 (400.99–442.74) 495.96 (455.92–536.01) 418.30 (414.01–422.59) 1–2: −74.1 (−119.3–28.9) 0.001
1–3: 3.6 (−17.7 24.9) 0.736
2–3: 77.7 (37.5118.0) 0.0002
Time-up-and-go
(seconds)
6.99 (6.90–7.08) 6.22 (5.76–6.689 6.44 (5.53–7.34) 7.03 (6.93–7.12) 1–2: −0.21 (−1.23 0.80) 0.681
1–3: −0.81 (−1.27–0.34) < .001
2–3: −0.59 (−1.51 0.32) 0.204
BODE Score 2.29 (2.21–2.37) 2.90 (2.52–3.29) 1.29 (0.55–2.02) 2.27 (2.19–2.35) 1–2: 1.62 (0.79 2.45) < .001
1–3: 0.63 (0.23 1.02) < .01
2–3: −0.99 (−1.73–0.25) < .01
~ point estimate (CI95%) Chi-Square p-value
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Table 2 Pulmonary function measurements reveal difference between AATD-COPD and COPD
Total (2645) 1 AATD + T (110) 2 AATD- T (29) 3 COPD (2506) Diff. between means (CI 95%)
p-value
FEV1 (L) 1.65 (1.63–1.68) 1.46 (1.32–1.59) 2.11 (1.85–2.37) 1.66 (1.63–1.68) 1–2: −0.65 (−094–0.36) < .0001
1–3: −0.20 (−0.33–0.06) < .001
2–3: 0.45 (0.19 0.71) < .001
FEV1% predicted 56.28 (55.84–57.08) 45.14 (41.25–49.02) 68.86 (61.29–76.43) 56.62 (55.81–57.44) 1–2: −23.72 (−32.2–15.2) < .0001
1–3: −11.50 (−15.4–7.5) < .0001
2–3: 12.3 (4.6 19.9) < .001
FVC % predicted 78.55 (77.82–79.28) 76.00 (72.42–79.55) 85.70 (78.76–92.64) 78.58 (77.83–79.33) 1–2: −9.71 (−17.5–1.9) 0.014
1–3: −2.58 (−6.22 1.06) 0.164
2–3: 7.12 (0.14 14.10) 0.046
FEV1/VC 0.55 (0.54–0.55) 0.46 (0.44–0.49) 0.61 (0.56–0.66) 0.55 (0.55–0.56) 1–2: −0.15 (−0.20–0.09) < .0001
1–3: −0.09 (−0.11–0.06) < .0001
2–3: 0.06 (0.01 0.10) 0.020
RV (L) 3.82 (3.77–3.87) 4.49 (4.26–4.7) 3.70 (3.26–4.15) 3.79 (3.75–3.84) 1–2: 0.79 (0.29 1.29) 0.002
1–3: 0.69 (0.46 0.93) < .0001
2–3: −0.09 (−0.54 0.35) 0.685
RV/ TLC nominal
value (%)
134.10 (133.00–135.29) 145.53 (140.15–150.91) 127.76 (117.43–138.08) 133.67 (132.54–134.80) 1–2: 17.77 (6.12 29.42) 0.003
1–3: 11.85 (6.35 17.35) < .0001
2–3: −5.91 (−16.31 4.48) 0.265
ITGV %
predicted
145.13 (143.69–146.58) 172.25 (165.29–179.22) 148.02 (134.58–161.47) 143.90 (142.43–145.36) 1–2: 24.23 (9.09 39.38) 0.002
1–3: 28.35 (21.23 35.47) < .0001
2–3: 4.12 (−9.41 17.64) 0.550
TLC (L) 7.13 (7.07–7.18) 8.18 (8.00–8.46) 7.46 (6.91–8.00) 7.08 (7.02–7.14) 1–2: 0.72 (0.11 1.33) 0.021
1–3: 1.11 (0.82 1.40) < .0001
2–3: 0.39 (−0.16 0.93) 0.165
sRaw eff %
predicted
170.90 (165.81–176.00) 179.28 (154.29–204.27) 120.75 (73.38–168.13) 171.14 (165.91–176.37) 1–2: 58.53 (4.94112.11) 0.032
1–3: 8.11 (−17.43 33.65) 0.534
2–3: −50.42 (−98.10–2.74) 0.038
TLCO %
predicted
55.01 (54.17–55.86) 43.92 (39.79–48.05) 56.49 (48.71–64.27) 55.47 (54.61–56.33) 1–2: −12.57 (−21.38–3.76) 0.005
1–3: −11.54 (− 15.77–7.33) < .0001
2–3: 1.02 (−6.82 8.85) 0.799
Fig. 1 The presence of AATD in males and female patients (broken line) is associated with a significant reduction of TLCO %pred as compared to
patients with COPD (straight line). The multivariate analysis included adjustment for airway obstruction in terms of FEV1% pred, lung hyperinflation in
terms of ITGV %pred and COPD risk factors in terms of packyears and BMI
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AATD patients. As compared to the COPD group,
HDL-cholesterol was higher and HbA1c was lower in
AATD patients independent of augmentation therapy.
Multivariate linear analyses adjusting for sex, age, pack-
years, FEV1%pred and BMI supported these findings
(parameter estimates, p-values): triglycerides as well as
HBa1c were lower in AATD patients as compared to
COPD (triglycerides −39.5 mg/dl, p < 0.001; HBa1c
−2.5 mmol/mol, p = 0.002). HDL-cholesterol was not
significantly different between AATD + T and AATD-T
(+2.4, p = 0.223), but cholesterol was significantly higher
in AATD-T group (+22.9, p = 0.038).
Discussion
The main finding of the present study is that AATD-
related lung disease is associated with fewer manifesta-
tions of periphery and coronary artery disease after cor-
rection for smoking, age and other potential confounders.
Non-deficient COPD is associated with comorbidi-
ties such as cardiovascular disease, lung cancer, or
osteoporosis [25, 26]. A recent study based on health
insurance data found a decreased prevalence of ische-
mic heart disease in AATD individuals as compared
to COPD patients [27]. In the present study, hyper-
tension, diabetes, coronary artery disease, heart fail-
ure, and alcoholism were reported significantly less
often in AATD as compared to non-AATD COPD.
The observed differences in comorbidities between
AATD-COPD and COPD patients are associated with
biochemical markers, such as significantly lower tri-
glyceride concentrations and lower HbA1c in AATD-
COPD than in COPD. After correction for potential
cofounders such as age, smoking history and BMI,
cardiovascular diseases were still found less frequent
among AATD-COPD as compared to COPD patients.
The observed differences in the prevalence of hyper-
cholesterolemia between the self-reported data (Fig. 3)
and the laboratory measurements (Table 3) could re-
sults from the different data sourced or the effect of
cholesterol-lowering therapies.
Fig. 2 Frequency of self-reported pulmonary comorbidities in patients with COPD, AATD + T and AATD-T (OR (CI95%) p-value, compared AATD + T
vs. COPD); TH = augmentation therapy
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This finding highlights the possibility of specific mech-
anisms in AATD and/or augmentation therapy that may
interfere with the development of cardiovascular disease.
There are several contradicting studies that highlight
this potential link: AATD patients have increased aortic
stiffness compared to control individuals without COPD,
as determined by aPWV [7]. This finding was replicated
in another study [28]. Earlier studies also observed a re-
duced blood pressure in AATD [9], however others
authors did not find such differences [29]. A genetic
study in the Copenhagen City Heart cohort revealed that
the systolic blood pressure is lower in PiZZ and PiMZ
individuals compared to PiMM or PiMS individuals.
However, PiMZ heterozygosity was associated with
increased age as a potential confounder [10]. A genetic
association study examined the frequency of AATD mu-
tations in patients with coronary atherosclerosis and
healthy controls and found an association of
Fig. 3 Distribution of extrapulmonal comorbidities in patients with COPD, AATD + T and AATD-T (OR (CI95%) p-value, compared AATD + T
vs. COPD)
Fähndrich et al. Respiratory Research  (2017) 18:171 Page 7 of 11
heterozygosity in the patient group [11]. As to our
knowledge, the present study is the first analysis of a dir-
ect comparison of non-deficient and AATD-based
COPD patients. It is important to point out that the as-
sociation of AATD with reduced frequencies of hyper-
tension and ischemic heart disease, or a low ABI (as
marker of peripheral artery disease) could only be dem-
onstrated for the combined AATD-T and AATD + T
group of patients. The low number of patients within
AATD-T subgroup (only 29 patients) did not allow a
separate statistical evaluation. Similarly, a previous study
based on insurance data [27] had no information on
augmentation therapy. Thus, we are not able to make a
firm conclusion whether our finding is associated with
AATD per se and/or with augmentation therapy. Based
on the small number of patients without augmentation,
no conclusion can be drawn about the effect of therapy.
The mechanisms that link AATD or augmentation therapy
with decreased frequency of cardiovascular disease are
speculative and may be related to the pleiotropic activities of
Fig. 4 Distribution of comorbidities in AAT-COPD patients: Forest plot for the adjusted influence of AATD (yes/no) on different comorbidities
(odds ratios are derived from multivariable logistic regression models)
Table 3 Comparison of laboratory investigations in patients with COPD and AATD (with and without augmentation therapy). For all
laboratory parameters, lsmean, diff-lsmean and CL95% and p-value from GLM are reported if not otherwise stated
Item Total a (n = 2645) 1 AATD + T (n = 110) 2 AATD-T (n = 29) 3 COPD (n = 2506) Diff. between means (CI 95%)
p-value
Creatinine serum [mg/dl] 0.89 (0.88–0.90) 0.86 (0.81–0.91) 0.75 (0.66–0.85) 0.89 (0.88–0.89) 1–2: 0.11 (−0.001 0.22) 0.053
1–3: −0.029 (−0.08 0.20) 0.243
2–3: −0.14 (−0.24–0.04) < .01
Uric acid [mg/dl] 5.95 (5.88–6.01) 5.5 (5.2–5.8) 5.2 (4.6–5.9) 5.9 (5.9–6.0) 1–2: 0.23 (−0.46 0.94): 0.509
1–3: −0.51 (−0.83–0.18) 0.002
2–3: −0.75 (−1.38–0.11) 0.021
alpha-1-antitrypsin [mg/dl] 142 (141–143) 113 (107–119) 39 (28–51) 144 (143–146) 1–2: 73.49 (60.46 86.51) < .0001
1–3: −31.94 (−38.07–25.82) < .0001
2–3: −105.43 (−117.05–93.81) < .0001
Triglyceride [mg/dl] 142 (138–146) 94 (73–116) 135 (93–178) 144 (140–149) 1–2: −41.02 (−88.55 6.51) 0.091
1–3: −50.56 (−72.35–28.76) < .0001
2–3: −9.53 (−52.24 33.17) 0.662
Cholesterol [mg/dl] 216 (215–217) 217 (209–225) 245 (229–261) 216 (214–218) 1–2: −27.91 (−46.38–9.44) 0.003
1–3: 1.27 (−7.17 9.71) 0.767
2–3: 29.18 (12.58 45.79) < .001
HDL Choles-terol [mg/dl] 65 (64–66) 71 (67–76) 75 (66–83) 64 (64–65) 1–2: −3.27 (−12.62 6.08) 0.491
1–3: 7.01 (2.69 11.32) 0.002
2–3: 10.27 (1.89 18.66) 0.016
LDL Choles-terol [mg/dl] 128 (127–130) 127 (120–135) 144 (130–159) 128 (126–129) 1–2: −17.15 (−33.70–0.60) 0.042
1–3: −0.57 (−8.21 7.07) 0.884
2–3: 16.58 (1.74 31.41) 0.029
HBA1c [mmol/mol] 41.2 (40.8–41.5) 37.1 (35.6–38.6) 37.1 (34.2–39.9) 41.4 (41.1–41.7) 1–2: 0.01 (−3.25 3.28) 0.994
1–3: −4.29 (−5.84–2.74) < .0001
2–3: −4.30 (−7.21–1.39) 0.004
aMean CL95% reported
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AAT [30, 31] These activities might include i) loss of vascu-
lar elastic recoil and decreased resistance due to excess activ-
ity of elastase; ii) upregulation and release of angiopoietin-
like protein 4 (Angptl4) by AAT in complex with fatty acids
[32–34].; iii) decreased production of inflammatory cyto-
kines, such as TNF-α and IL-1β by AAT [35]. In addition, a
protective role for AAT was demonstrated in the Lipid Cor-
onary Angiography Trial that evaluated male participants
after coronary bypass surgery [12]. Altogether, the data above
suggest that the mechanisms that links AATD or augmenta-
tion therapy with decreased frequency of cardiovascular dis-
ease are likely related to the pleiotropic activities of AAT
protein. The effect of AATD on cardiovascular risk might
represent an advantageous consequence of the SERPINA1
mutation, in addition to a proposed selective anti-infective
advantage by increased inflammation [36].
The present study revealed additional characteristics
of AATD-related lung disease. Patients with AATD sig-
nificantly more often reported the presence of bronchi-
ectasis, which is in line with previous data [8]. Another
study analyzed the distribution of AATD alleles among
patients with bronchiectasis and found an even distri-
bution between patients and controls [37]. The analysis
of the lung phenotype revealed an out-of-proportion
loss of diffusion capacity. AATD lung disease is associ-
ated with panlobular emphysema, with a predominance
in the lower lobe, and with a loss of elastic recoil pres-
sure [38, 39]. CT studies have shown heterogeneity of
the distribution of emphysema [40, 41]. Indeed, AATD
was associated with a significant reduction of TLCO
%pred after adjustment for ITGV%pred as well as
FEV1%pred, packyears and BMI as other potentially
relevant confounders. A defect of diffusion capacity is
known to associate with worse quality of life [41] and a
decrease of KCO was associated with apical loss of lung
parenchyma in CT [40].
Several limitations of the present study have to be taken
into account: In the present study the information on
comorbidities was based on self-reported statements of a
doctor’s diagnosis. Although the COSYCONET cohort
study is a multicenter study with a large number of
patients, the number of AATD individuals with or without
augmentation therapy is limited. The low number of pa-
tients without therapy made it difficult to discriminate
whether the effect of AATD on cardiovascular risk is asso-
ciated with the disease or with augmentation therapy.
Genotyping data on the SERPINA1 gene were only avail-
able for a minority of the patients. Nevertheless, the
applied grouping algorithm likely results in a correct sep-
aration of individuals with severe AATD. The recruitment
strategy of COPD and AATD patients was likely different
and could account for a selection and confounding bias.
Data on the time course of augmentation therapy were
not available.
Conclusion
In conclusion, within the German COPD cohort COSYC-
ONET we found that AATD is associated with a lower num-
ber of cardiovascular comorbidities even after adjustment for
confounders. The underlying mechanisms are currently un-
clear. These data add to the understanding of the complex
biology of AATD and indicated that AATD likely impacts on
processes involved in cardiovascular disease.
Additional file
Additional file 1: Table S1. Analysis of lung density by CT (available for
379 patients). (f) n = 3 missings, (g) n = 89 missings, *panlobular
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linear regression model with TLCO %pred. as dependent variable. AATD
refers to the presence of AATD versus COPD. Figure S1. Patients with
AATD revealed a reduced TLCO %pred at similar levels of ITGV %pred. (A,
B) or BMI (B, D) for both female and male patients after adjustment for
FEV1, sex, BMI, packyears, and age (AATD - dotted line, COPD - straight
line). Table S3. Results (Odds Ratio [95% confidence interval] and
p-value) of multivariable logistic regression analyses for different
comorbidities as dependent variable. (DOCX 265 kb)
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